| Domain | Finding | Evidence type (human/mouse/rat) | Key details (numbers/doses) | Primary source (authors/year/journal) | URL |
|---|---|---|---|---|---|
| Inheritance | BCKDK deficiency is an autosomal recessive disorder caused by biallelic loss-of-function variants in **BCKDK** | Human | Initial report: 3 consanguineous pedigrees with 2 affected individuals each (6 affected total); recessive segregation supported by homozygous variants in affected individuals (pqac-00000005, pqac-00000006) | Novarino et al., 2012, *Science* | https://doi.org/10.1126/science.1224631 |
| Clinical features | Core phenotype includes autism/intellectual disability/epilepsy; later reports expand spectrum to developmental and epileptic encephalopathy, microcephaly, absent speech, psychomotor delay, regression, and neurobehavioral abnormalities | Human | Science 2012 families: autism, ID, epilepsy (pqac-00000005, pqac-00000006); 2022 siblings: psychomotor delay from first year, subacute regression in second year in 2/3, progressive microcephaly, absent speech, early generalized seizures (pqac-00000003, pqac-00000004) | Novarino et al., 2012, *Science*; Boemer et al., 2022, *Int J Mol Sci* | https://doi.org/10.1126/science.1224631 ; https://doi.org/10.3390/ijms23042253 |
| Biochemical signature | Loss of BCKDK causes reduced phosphorylation/inhibition of BCKDH, increased BCAA catabolism, and low plasma/CSF branched-chain amino acids | Human | Reduced BCKDK mRNA/protein and loss of phospho-E1α signal in patient cells; markedly reduced plasma BCAA in affected individuals (pqac-00000006, pqac-00000012); 2022 family had severely reduced plasma and CSF BCAA and low newborn-screen dried-blood-spot markers (pqac-00000003, pqac-00000004) | Novarino et al., 2012, *Science*; Boemer et al., 2022, *Int J Mol Sci* | https://doi.org/10.1126/science.1224631 ; https://doi.org/10.3390/ijms23042253 |
| Pathogenic variants | Human pathogenic variants reported include **p.M74fs**, **p.Arg156\***, **p.Arg224Pro**, and **p.Thr334del** | Human | p.M74fs, p.Arg156\*, p.Arg224Pro identified in 2012 families (pqac-00000005, pqac-00000012); homozygous in-frame deletion c.999_1001delCAC (**p.Thr334del**) identified in 3 siblings and shown functionally deleterious (pqac-00000003, pqac-00000004) | Novarino et al., 2012, *Science*; Boemer et al., 2022, *Int J Mol Sci* | https://doi.org/10.1126/science.1224631 ; https://doi.org/10.3390/ijms23042253 |
| Model organism variant | Spontaneous rat model carries **Bckdk G369E**, a missense loss-of-function variant affecting kinase activity | Rat | Homozygous **G369E** segregates with central and peripheral nervous system phenotype; markedly decreased Ser293 phosphorylation and sharply decreased plasma BCAA (pqac-00000013) | Zigler et al., 2016, *PLOS ONE* | https://doi.org/10.1371/journal.pone.0160447 |
| Mouse model | **Bckdk−/−** mice recapitulate neurological disease features and biochemical abnormalities | Mouse | Altered brain amino acid levels, hindlimb clasping, seizures; rescue experiments used BCAA-enriched diets including 7% BCAA and transition to 2% BCAA diets (pqac-00000005, pqac-00000012) | Novarino et al., 2012, *Science* | https://doi.org/10.1126/science.1224631 |
| Rat model | Frogleg rat demonstrates both central and peripheral nervous system involvement from Bckdk dysfunction | Rat | Phenotype linked to unchecked BCKDH activity, excessive BCAA catabolism, and deficient circulating BCAA; structural modeling predicted disruption of kinase domain/ADP binding (pqac-00000013) | Zigler et al., 2016, *PLOS ONE* | https://doi.org/10.1371/journal.pone.0160447 |
| Treatment evidence | BCAA supplementation is the main reported disease-directed therapy; high-protein diet plus oral leucine/isoleucine/valine can restore plasma BCAA and improve seizures | Human | 2022 sibling series used protein-rich diet **2.5-3 g/kg/day** plus oral L-leucine/L-isoleucine/L-valine; initial **~85-125 mg/kg/day each** was insufficient, increased to **~135-195 mg/kg/day each** in divided doses achieved physiological plasma levels; seizure control greatly improved (pqac-00000003, pqac-00000004, pqac-00000000) | Boemer et al., 2022, *Int J Mol Sci* | https://doi.org/10.3390/ijms23042253 |
| Treatment outcomes | Clinical benefit appears strongest for seizure control; developmental/behavioral gains are more limited and may depend on early treatment | Human | One child had **10 hospital admissions** in the year before therapy versus **1 admission during 18 months** on therapy; Vineland scores improved, especially communication/socialization, but behavioral/developmental gains were less robust than seizure benefit (pqac-00000000, pqac-00000002) | Boemer et al., 2022, *Int J Mol Sci* | https://doi.org/10.3390/ijms23042253 |
| Newborn screening relevance | Low BCAA on dried blood spots suggests potential newborn-screening detectability | Human | Retrospective review showed low Xle and valine on NBS; example patient values included **Xle 84 µmol/L** and **Val 47 µmol/L** on newborn screening (pqac-00000003, pqac-00000004) | Boemer et al., 2022, *Int J Mol Sci* | https://doi.org/10.3390/ijms23042253 |
| 2024 therapeutic caveat | Newer mouse work challenges the assumption that enteral BCAA supplementation is sufficient or uniformly beneficial | Mouse | In **Bckdk−/−** mice, enteral BCAA supplementation increased systemic BCAA but **exacerbated neurodevelopmental deficits** and did not correct biochemical abnormalities; CSF/brain BCAA remained low (pqac-00000007, pqac-00000008, pqac-00000009) | Ohl et al., 2024, *Mol Genet Metab Rep* | https://doi.org/10.1016/j.ymgmr.2024.101091 |
| 2024 alternative preclinical strategy | Partial suppression of downstream BCAA catabolism may be a more effective strategy than simple supplementation | Mouse | **Dbt haploinsufficiency** partially rescued microcephaly, neurodevelopmental phenotypes, survival, weight, and many biochemical abnormalities in **Bckdk−/−** mice (pqac-00000008, pqac-00000009) | Ohl et al., 2024, *Mol Genet Metab Rep* | https://doi.org/10.1016/j.ymgmr.2024.101091 |


*Table: This table summarizes core disease characteristics of BCKDK deficiency across human cases and animal models, including inheritance, phenotype, biochemical signature, variants, and treatment evidence. It also highlights the important 2024 preclinical finding that enteral BCAA supplementation may not fully correct brain disease and can worsen some mouse outcomes.*